Location · Bryant, AR
Clinical trials in Bryant, AR
15 recruiting studies have a site in Bryant, and 0 of them accept healthy volunteers.
15 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Sagimet Biosciences Inc.
- Location
- Bryant, AR + 17 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
Pfizer
- Location
- Bryant, AR + 11 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Bryant, AR + 33 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 2
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Takeda
- Location
- Bryant, AR + 20 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Janssen Research & Development, LLC
- Location
- Bryant, AR + 41 other US sites
- Eligibility basics
- Ages 18–74
- RecruitingPhase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Bryant, AR + 44 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Neurocrine Biosciences
- Location
- Bryant, AR + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
- Location
- Bryant, AR + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 2
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
AbbVie
- Location
- Bryant, AR + 32 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Bryant, AR + 11 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 4
Study to Assess Safety, Pharmacokinetics, and Treatment Effect of Cabtreo
Bausch Health Americas, Inc.
- Location
- Bryant, AR + 13 other US sites
- Eligibility basics
- Ages 9–11
- RecruitingPhase 3
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Neurocrine Biosciences
- Location
- Bryant, AR + 38 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Neurocrine Biosciences
- Location
- Bryant, AR + 17 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Neurocrine Biosciences
- Location
- Bryant, AR + 20 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries, Inc.
- Location
- Bryant, AR + 53 other US sites
- Eligibility basics
- Ages 12–17